

I hereby certify that on December 31, 2009, which is the date I am signing this certificate, I am transmitting this correspondence and all identified attachments electronically to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

/Sarah Kim/

Sarah Kim

Applicant: **BAMDAD, Cynthia C.**
 Serial No.: **10/564,981**
 Filed: **January 13, 2006**
 Confirmation No.: **4121**
 Title: **METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER**
 Examiner: **MCDOWELL, Brian E.**
 Art Unit: **1624**
 Attorney Docket No.: **13150-70090US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08B and PTO/SB/08A (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

Foreign Patent Documents:

WO 03/070701 A, Cytokinetics Inc., August 28, 2003
WO 03/097053 A, Cytokinetics Inc., November 27, 2003
WO 2004/055008 A, Smithkline Beecham Corp., July 1, 2004
WO 2005/051922 A, Chipron Corp., June 9, 2005

English Language Non-Patent Documents:

Ciborowski and Finn, "Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: Potential role in metastasis," Clinical and Experimental Metastasis, 19(4):339-345, 2002
--

Morse, "Technology evaluation: BLP-25, Biomira Inc.," Current Opinion in Molecular Therapeutics, Current Drugs, 3(1):102-105, February 1, 2001
Hinoda et al., "Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissue or cells," J. of Gastroenterology, 33(2):164-171, April 1998
Chen et al., "Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter," J. of Clinical Investigation, 96(6):2775-2782, December 1995

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

Since the present Information Disclosure Statement is being timely submitted within three (3) months from the Supplementary European Search Report issue date in the counterpart European application, it is believed that no fee is required for this submission.

Also enclosed is a copy of the Supplementary European Search Report from the counterpart European application citing the above-listed references.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

December 31, 2009
Date

/Joseph Hyosuk Kim/
Joseph Hyosuk Kim, Ph.D.
Reg. No. 41,425
Attorney for Applicants

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: (818) 249-8177
Facsimile: (818) 249-8277